VORICONAZOLE FOR INJECTION 200 MG
VORICONAZOLE : 200 MG · DIN 02493829 · FRESENIUS KABI CANADA LTD
Health Canada status: MARKETED
What is VORICONAZOLE FOR INJECTION?
VORICONAZOLE FOR INJECTION 200 MG contains VORICONAZOLE : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02493829, held by FRESENIUS KABI CANADA LTD, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 01-Sep-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VORICONAZOLE FOR INJECTION used for?
Voriconazole for Injection (voriconazole) is indicated for: Invasive aspergillosis; Candidemia in non-neutropenic patients and the following Candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall and wounds.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02493829 |
|---|---|
| Brand name | VORICONAZOLE FOR INJECTION |
| Generic / active ingredient | VORICONAZOLE : 200 MG |
| Manufacturer | FRESENIUS KABI CANADA LTD |
| Strength | 200 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J02AC03 VORICONAZOLE |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-Sep-2021 |
| Original market date | 2021-09-01 00:00:00 |
How is it stored and handled?
Once reconstituted, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should not be longer than 24 hours at 2 °C to 8 °C (36 °F to 46 °F).
How is it supplied?
200 mg / vial, 3200 mg SBECD
Is VORICONAZOLE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J02AC03 VORICONAZOLE. 11 of 27 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP VORICONAZOLE | 200 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02525798 |
| JAMP VORICONAZOLE | 50 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02525771 |
| SANDOZ VORICONAZOLE | 200 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02399253 |
| SANDOZ VORICONAZOLE | 50 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02399245 |
| VFEND | 200 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02256487 |
| VFEND | 200 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02256479 |
| VFEND | 200 MG / 5 ML | POWDER FOR SUSPENSION | PFIZER CANADA ULC | MARKETED | DIN 02279991 |
| VFEND | 50 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02256460 |
| VORICONAZOLE FOR INJECTION | 200 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02381966 |
| VORICONAZOLE FOR INJECTION | 200 MG | POWDER FOR SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02477696 |
Who else supplies VORICONAZOLE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. VORICONAZOLE appears in 194 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.